This report assesses the pharmaceutical sector in India, particularly focusing on four key issues related to the production, procurement, and distribution of drugs in India: a) availability, b) affordability; c) quality, and d) the rational use of drugs. The results of a survey of three states...

In ‘K-economy', intangible assets are playing an important role in the creation and maximization of wealth of shareholders. The investors also attach greater significance to such assets in evaluating their investments in different companies. This study examines the voluntary disclosure...

Novartis spent nearly 15 years seeking a patent in India for Glivec. That quest reached its dead end, at last, on April 1st. India's Supreme Court rejected the Swiss drugmaker's patent. It represents critical issues related to intellectual property protection and access to medicines, which will...

In 2005, as the result of a World Trade Organization mandate, India began to implement product patents for pharmaceuticals that were compliant with the 1995 Trade-Related Aspects of Intellectual Property Rights (TRIPS). We combine pharmaceutical product sales data for India with a newly gathered...

Background: Active Pharmaceutical Ingredient (API) manufacturing is an important segment of the Indian pharma industry. India ranks third in terms of volume of medicines produced, and is a major global supplier of generic medicines. However, India depends heavily on the import of several raw...

The TRIPS agreement has been one of the most contentious agreements of WTO. The pharmaceutical industry has been central to this debate, especially the case of India, which did not recognize product patents in pharmaceuticals before TRIPS and evolved as a major pharmaceuticals manufacturer and...